Roles
- Professor of Neurology and Public Health Sciences
- Chief, Neuromuscular Division
- Executive Director, The ALS Center
- Vice Chair, Clinical and Translational Research, Department of Neurology
-
Biography
Dr. Michael Benatar, MD, PhD - is a Professor of Neurology and of Public Health Sciences, Chief of Neuromuscular Division, and Vice Chair for Clinical and Translational Research in the Department of Neurology. He is the Walter Bradley Chair in ALS Research and the Executive Director of the ALS Center at the University of Miami. He obtained his medical degree at the University of Cape Town in South Africa and is also trained in both basic neuroscience (DPhil, Oxford) and clinical research methods (Masters in the Science of Clinical Research Emory). He leads an active clinical and translational research program focused on biomarker and therapy development for ALS. He is the PI of the ongoing Pre-Symptomatic Familial ALS (Pre-fALS) study as well as the CReATe Consortium, a rare diseases clinical research consortium focused on ALS and related neurodegenerative diseases. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
Global ALS Leaders Convene to Transform Neuroscience Discovery into New Treatments
FastTrack ALS Clinic Accelerates Diagnosis and Personalized UHealth Care
Researchers Launch $26 Million Study to Predict ALS and FTD Before Symptoms Begin
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 6 clinical trials.
-
An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation
- Principal Investigator: Michael Benatar
- Study Phase: Phase 3
- Enrollment Status: Closed
-
The purpose of this research study is to learn about changes in the brain related to Amyotrophic Lateral Sclerosis (ALS) and other motor neuron diseases by using advanced Magnetic Resonance Imaging (MRI) techniques. The aim of this study is to improve our understanding of the symptoms and progression of ALS, as well as to use these advanced MRI methods to aim in earlier diagnosis and the evaluation of new treatments.
- Principal Investigator: Michael Benatar
- Study Phase: N/A
- Enrollment Status: Closed
-
The overarching goal of this clinical research program in the field of ALS is to improve our understanding of the underlying biology of ALS and related neurodegenerative disorders such as fronto temporal dementia (FTD) and multisystem proteinopathy (MSP). Furthermore, we aim to better define and characterize the onset of the disease process by studying presymptomatic individuals who are at risk of developing ALS. We aim to accomplish our goals by studying the following groups of people:1. ALS Affected individuals either sporadic or familial. Individuals in this group may also be participating in the Arimoclomol (eProst ID 20100758) clinical trial for the treatment of ALS.2. Unaffected individuals from familial ALS pedigrees, including presymptomatic individuals at risk for ALS. Depending on these participants prior knowledge of their genetic status and their desire to learn the results of genetic testing, we divide this population into three groups:a. Disclosure group: participants in this group have elected to learn the results of genetic testingb. NonDisclosure group: participants in this group have elected not to learn the results of genetic testingc. Known status: participants in this group have already undergone genetic testing outside of our research study and have documentation showing their genetic test results.3) ALSRelated Neurodegenerative Disorder Affected Individuals (e.g., FTD, MSP).4) Healthy controls, which may include UM employees.The objectives and aims of this study can be summarized as follows:1. Identify the genetic cause of disease in families with ALS and related neurodegenerative disorders.2. Characterize the presymptomatic phase of ALS.3. Characterize the early symptomatic stages of ALS using both clinical and biomarker studies.4. Investigate potential environmental and genetic modifiers of disease phenotype in ALS and related neurodegenerative disorders. 5. Develop a repository of samples rigorously collected longitudinally from people at genetic risk for ALS and from those with ALS and related neurodegenerative disorders. 6. Define the relationship between ALS and other related neurodegenerative disorders. 7. Collect biomarkers in healthy controls.
- Principal Investigator: Michael Benatar
- Study Phase: N/A
- Enrollment Status: Open
-
An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
- Principal Investigator: Michael Benatar
- Study Phase: Phase 1
- Enrollment Status: Closed
-
HEALEY ALS Platform Trial
- Principal Investigator: Michael Benatar
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Closed
-
A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
- Principal Investigator: Michael Benatar
- Study Phase: Phase 3
- Enrollment Status: Not Accepting